12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.

PFIZER S.A.,0 个研究点目标入组 0 人开始时间: 2008年9月24日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: PFIZER S.A.,

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 80（—）

入选标准

•Outpatient male or female patients> 18 years of age.
•Overactive bladder symptoms (reported by the patient) for> 3 months before the selection / enrollment visit (visit 1)
•Have reported, on average, 1 episode of UUI per 24 hours in the 3-day voiding card before the randomization / baseline visit (visit 2)
•Average urinary frequency of> 8 micturition for 24 hours as verified by the micturition chart before the randomization / baseline visit (visit 2)
•Able and interested in completing the voiding booklets and all the questionnaires related to the study and in complying with the scheduled clinical visits and the clinical study procedures.
•Trained to understand and having signed the informed consent form after a detailed discussion of the nature of the treatment investigation and its risks and benefits

排除标准

•Any condition that may contraindicate your use of fesoterodine including: hypersensitivity to the active substance (fesoterodine fiimarate) or peanut or soy or any of the excipients, urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, insufficiency severe liver disease (Child Pugh C), severe ulcerative colitis, and toxic megacolon
•Clinically significant liver or kidney disease, and / or a test to select AST, ALT, ALP, urea nitrogen, or creatinine greater than 1.5 times the upper limit of the normal range (ULN)
•Neurological conditions such as stroke, multiple sclerosis, spinal cord injury, or Parkinson´s disease, which is known or suspected to influence bladder function of the subject.
•Prolapse of the pelvic organ stage 3 or more defined as visible tissue through the introitus in the position of resting lithotomy (without increase in intra-abdominal pressure)
•History of lower urinary tract surgery (for example, surgery for incontinence or surgery to reduce the size of the prostate) within the last 6 months
•A known history of interstitial cystitis or significant pain component associated with symptoms of overactive bladder, untreated hematuria, urogenital cancer, interstitial or external radiation to the pelvis or external genital organs, or obstruction of bladder outlet due to contraction of the bladder neck, clinical suspicion of carcinoma to the prostate, mullerian duct cysts, urethral obstruction due to narrowing / valves / sclerosis or urethral tumor, radiation cystitis, genitourinary tuberculosis, bladder stones, or detrusor-sphincter dyssynergia.
•Prior history of acute urinary retention that requires catheterization, or severe evacuation difficulties in the case of the investigator, before the baseline
•Use of an internal catheter or an intermittent auto-catheterization program
•Incontinence symptoms that are predominantly of the stress urinary incontinence type as determined by the investigator
•Polyuria (> 3000mL / 24hrs.) Or an evacuated volume> 500mL for any urination during the period of admission
•Urinary tract infection (UTI) as demonstrated by the urinalysis results of recurrent urinary tract infection or selection (TIUR) defined as treatment for UTI> 3 times during the previous year
•The use of any type of electrostimulation, bladder training, or pelvic floor exercises (with doctors specialized in incontinence) within 4 weeks prior to visit 1
•Have received study medication in a clinical trial with feosterodine.
•Treatment with the following drugs within 2 weeks prior to visit 1: Any pharmacological treatment for overactive bladder, including antimuscarinic medication for OAB, Any drug with significant anticholinergic or antispasmodic effects.
•Have begun treatment with tricyclic antidepressants or estrogens within 4 weeks prior to Visit 1 and / or not be in a stable dose.
•Have begun treatment with diuretics or alpha blockers within 2 weeks prior to Visit 1 and / or not be in a stable dose.
•Treatment with potent inhibitors of CYP3 A4, such as clarithromycin, ketoconazole and itraconazole within 2 weeks prior to visit 1.
•Administration of drugs capable of inducing the metabolism or transport of liver enzymes (such as barbiturates, rifampicin, carbamazepine, phenytoin, pyrmidone, or St. John´s Wort) during the 2 weeks prior to visit 1.
•Treatment with any investigational drug duri

研究者

发起方

PFIZER S.A.,

相似试验

已完成

不适用

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)-N328 Other specified disorders of bladderOther specified disorders of bladderN328

PER-035-07PFIZER S.A.,

撤回

3 期

12-week, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder.loss of urinaryurgency urinary incontinence10004994

NL-OMON31014Pfizer50

已完成

4 期

This study is designed to compare how safe and effective salmeterol /fluticasone combination is when given with an autohaler or inhaler device in asthma patients

CTRI/2011/11/002165Cipla Ltd150

进行中（未招募）

不适用

A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5µg bid and 2x80/4.5 µg bid compared to Formoterol Turbuhaler 2x4.5µg bid and Placebo in patients with chronic obstructive pulmonary disease (COPD). - SThis is an application for a phase III study to be conducted in COPD patients.Classification code 10010952

EUCTR2004-001168-28-ISAstraZeneca AB1,600

进行中（未招募）

1 期

EUCTR2004-001168-28-DKAstraZeneca AB1,600